107 related articles for article (PubMed ID: 6592381)
1. Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
Favrot MC; Philip I; Philip T; Portoukalian J; Doré JF; Lenoir GM
J Natl Cancer Inst; 1984 Oct; 73(4):841-7. PubMed ID: 6592381
[TBL] [Abstract][Full Text] [Related]
2. B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
Cohen JH; Revillard JP; Magaud JP; Lenoir G; Vuillaume M; Manel AM; Vincent C; Bryon PA
J Natl Cancer Inst; 1987 Feb; 78(2):235-42. PubMed ID: 3027441
[TBL] [Abstract][Full Text] [Related]
3. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Gregory CD; Tursz T; Edwards CF; Tetaud C; Talbot M; Caillou B; Rickinson AB; Lipinski M
J Immunol; 1987 Jul; 139(1):313-8. PubMed ID: 2953817
[TBL] [Abstract][Full Text] [Related]
4. An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas.
Payne CM; Grogan TM; Cromey DW; Bjore CG; Kerrigan DP
Lab Invest; 1987 Aug; 57(2):200-18. PubMed ID: 3497304
[TBL] [Abstract][Full Text] [Related]
5. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics.
Magrath IT; Pizzo PA; Whang-Peng J; Douglass EC; Alabaster O; Gerber P; Freeman CB; Novikovs L
J Natl Cancer Inst; 1980 Mar; 64(3):465-76. PubMed ID: 6243721
[TBL] [Abstract][Full Text] [Related]
6. Immunologic markers of Burkitt's lymphoma cells.
Preud'homme JL; Dellagi K; Guglielmi P; Vogler LB; Danon F; Lenoir GM; Valensi F; Brouet JC
IARC Sci Publ; 1985; (60):47-64. PubMed ID: 3864747
[TBL] [Abstract][Full Text] [Related]
7. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma.
Rowe M; Rooney CM; Rickinson AB; Lenoir GM; Rupani H; Moss DJ; Stein H; Epstein MA
Int J Cancer; 1985 Apr; 35(4):435-41. PubMed ID: 2985508
[TBL] [Abstract][Full Text] [Related]
8. Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Sieverts H; Alabaster O; Goldschmidts W; Magrath I
Cancer Res; 1986 Mar; 46(3):1182-8. PubMed ID: 3080238
[TBL] [Abstract][Full Text] [Related]
9. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
10. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
11. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Szekely L; Pokrovskaja K; Klein G
Cell Growth Differ; 1997 May; 8(5):599-609. PubMed ID: 9149911
[TBL] [Abstract][Full Text] [Related]
13. 38.13: a monoclonal antibody directed against a Burkitt's lymphoma-associated antigen and its use as carrier for toxins.
Wiels J; Balaña A; Tursz T
IARC Sci Publ; 1985; (60):457-64. PubMed ID: 4065950
[TBL] [Abstract][Full Text] [Related]
14. [A monoclonal antibody, specific for Burkitt's lymphoma, is also a blood group Pk antibody].
Fellous M; Wiels J; Cartron JP; Tursz T
Dev Biol Stand; 1984; 57():293-8. PubMed ID: 6084615
[TBL] [Abstract][Full Text] [Related]
15. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
[TBL] [Abstract][Full Text] [Related]
16. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
17. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
Rooney CM; Gregory CD; Rowe M; Finerty S; Edwards C; Rupani H; Rickinson AB
J Natl Cancer Inst; 1986 Sep; 77(3):681-7. PubMed ID: 2943927
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma.
Rowe M; Rooney CM; Edwards CF; Lenoir GM; Rickinson AB
Int J Cancer; 1986 Mar; 37(3):367-73. PubMed ID: 3005176
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-associated Burkitt's lymphoma in India.
Venkitaraman AR; John TJ; Rangad F; Singh AD; Date A; Lenoir G
Trop Geogr Med; 1983 Sep; 35(3):273-7. PubMed ID: 6316592
[TBL] [Abstract][Full Text] [Related]
20. A novel Japanese Burkitt's lymphoma cell line, P32/Ishida, with a new variant chromosomal translocation (2;14).
Hirose M; Minato K; Tobinai K; Ise T; Watanabe S; Shimoyama M; Abe T
Gan; 1983 Dec; 74(6):878-86. PubMed ID: 6667834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
